Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving viable micro-organism
Reexamination Certificate
2008-01-01
2008-01-01
Gitomer, Ralph (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving viable micro-organism
C435S030000, C435S032000, C435S261000
Reexamination Certificate
active
11081827
ABSTRACT:
The present invention discloses in vitro methods for screening candidate therapeutic and/or chemotherapeutic agents for in vivo efficacy in a specific patient. The invention also includes methods for determining the optimal dosage of a therapeutic agent for a specific patient. The methods include the use of cohesive multicellular particulates of tissue, rather than enzymatically dissociated cell suspensions or preparations, to prepare tissue culture monolayers representative of in vivo cell populations.
REFERENCES:
patent: 4423145 (1983-12-01), Stampfer et al.
patent: 4559299 (1985-12-01), Rotman
patent: 4668618 (1987-05-01), Thornthwaite
patent: 4816395 (1989-03-01), Hancock et al.
patent: 4937182 (1990-06-01), Hancock et al.
patent: 4937187 (1990-06-01), Rotman
patent: 4996145 (1991-02-01), Weisenthal
patent: 5242806 (1993-09-01), Yen-Maguire et al.
patent: 5270172 (1993-12-01), Morgan
patent: 5403574 (1995-04-01), Piwnica-Worms
patent: 5443950 (1995-08-01), Naughton et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5705270 (1998-01-01), Soon-Shiong et al.
patent: 5728541 (1998-03-01), Kornblith
patent: 5789158 (1998-08-01), Knowles et al.
patent: 5874218 (1999-02-01), Drolet et al.
patent: 5888765 (1999-03-01), Patterson et al.
patent: 5942385 (1999-08-01), Hirth
patent: 5972639 (1999-10-01), Parandoosh
patent: 6008007 (1999-12-01), Fruehauf et al.
patent: 6020473 (2000-02-01), Keyt et al.
patent: 6069134 (2000-05-01), Roth et al.
patent: 6111092 (2000-08-01), Williamson
patent: 6261795 (2001-07-01), Fruehauf et al.
patent: 6274576 (2001-08-01), Grimley et al.
patent: 6303324 (2001-10-01), Fruehauf
patent: 6335170 (2002-01-01), Orntoft
patent: 6416967 (2002-07-01), Kornblith
patent: 6511806 (2003-01-01), Fruehauf et al.
patent: 6664062 (2003-12-01), Stanton, Jr.
patent: 6887680 (2005-05-01), Kornblith
patent: 6900027 (2005-05-01), Kornblith
patent: 6933129 (2005-08-01), Kornblith
patent: 7112415 (2006-09-01), Kornblith
patent: 2001/0051353 (2001-12-01), Kornblith
patent: 2002/0168679 (2002-11-01), Naus et al.
patent: 2002/0192638 (2002-12-01), Kornblith
patent: 2003/0096290 (2003-05-01), Fruehauf et al.
patent: 2004/0023375 (2004-02-01), Kornblith et al.
patent: 2004/0072722 (2004-04-01), Kornblith et al.
patent: 2004/0086888 (2004-05-01), Kornblith et al.
patent: 2005/0202410 (2005-09-01), Kornblith
patent: 2007/0037136 (2007-02-01), Kornblith
patent: 2007/0059821 (2007-03-01), Kornblith et al.
patent: WO 96/10742 (1996-04-01), None
patent: WO 98/02038 (1998-01-01), None
patent: WO 02/33117 (2002-04-01), None
patent: WO 2004/015065 (2004-02-01), None
patent: WO 2004/035833 (2004-04-01), None
Alley, M., “Morphometric and Colorimetric Analysis of Human Tumor Cell Line Growth and Drug Sensitivity in Soft Agar Culture,” Cancer Research, 51:1247-1256 (1991).
Andreotti, P., “TCA-100 Tumour Chemosensitivity Assay: Differences in Sensitivity between Cultured Tumour Cell Lines and Clinical Studies,” J. Biolumin. Chemilumin., 9:373-378 (1994).
Arnold, J., et al., “Evaluation of Chemopreventive Agents in Different Mechanistic Classes Using a Rat Tracheal Epithelial Cell Culture Transformation Assay,” Cancer Research, 55:537-543 (1995).
Becton-Dickinson Catalog, Anti-Cytokeratin (CAM 5.2) Reagant, pp. 1-11 (1997).
Boehringer Mannheim Catalog, Anti-Cytokeratin AE1/AE3 (1996).
Bosanquet, Andrew G., “Short-term In Vitro Drug Sensitivity Tests for Cancer Chemotherapy. A Summary of Correlations of Test result with Both Patient Response and Survival”, Forum 4(2):179-195 (1994).
Broadley, C., et al., “A Tissue-Culture Model for the Study of Canine Vocal Fold Fibroblasts,” Laryngoscope, 105(1):23-27 (1995).
Burczynski, M., et al., “Toxicogenomics-Based Discimination of Toxic Mechanism in HepG2 Human Hepatoma Cells,” Toxicological Sciences, 58(2):399-415 (2000).
Cilley, R., et al., “Fetal Lung Development: Airway Pressure Enhances the Expression of Developmental Genes,” Journal of Pediatric Surgery, 35(1):113-119 (2000).
DAKO Catalog, Specification Sheet for Monoclonal Mouse Anti-Human Epithelial Membrane Antigen, pp. 1-2 (1996).
Dietel, M., et al., “In Vitro Prediction of Cytostatic Drug Resistance in Primary Cell Cultures of Solid Malignant Tumours,” Eur. J. Cancer, 29A(3):416-420 (1993).
Dudley, D., et al., “A Human Endometrial Explant System: Validation and Potential Applications,” Am. J. Obstet. Gynecol., 167(6):1774-1780 (1992).
European Search Report for EP 97 93 3267 dated May 3, 2002.
Freshney, R.I., Culture of Animal Cells, 3rd edition, Wiley-Liss, pp. 127-147, 153-156, and 349-356 (1994).
Freshney, R.I., Culture of Animal Cells: A Manual of Basic Technique, 2nd edition, pp. 107, 124-126, 179, 233-234, 290 (1987).
Fruehauf, J.P. “In Vitro Assay-Assisted Treatment selection for Women with Breast or Ovarian Cancer”, Endocrine-Related Cancer, 9:171-182 (2002).
Frykholm, G., et al., “Heterogeneity in Antigenic Expression and Radiosensitivity in Human Colon Carcinoma Cell Lines,” In Vitro Cell Dev. Biol., 27A:900-906 (1991).
Fulda, S., et al., “Antiproliferative Potential of Cytostatic Drugs on Neuroblastoma Cells In Vitro,” Eur. J. of Cancer., 31A(4):616-621 (1995).
Gamboa, G., et al., “Characterization and Development of UCI 107, a Primary Human Ovarian Carcinoma Cell Line,” Gynecologic Oncology, 58:336-343 (1995).
Gerweck, et al., “Radiation Sensitivity of Cultured Human Glioblastoma Cells,” Radiology, 125(1):231-234 (1977).
Ghosh, A., et al., “Immunohistological Staining of Reactive Mesothelium, Mesothelloma and Lung Carcinoma with a Panel of Monoclonal Antibodies,” J. Clin. Pathol., 40:19-25 (1987).
Goldsworthy, T., et al., “Concepts, Labeling Procedures, and Design of Cell Proliferation Studies Relating to Carcinogenesis,” Environmental Health Perspectives, 101(supp. 5):59-66 (1993).
Gress, T., et al., “Development of a Database on Transcribed Sequences in Tumour Cells and Identification of Changes in Transcription Patterns Related to Transformation and Other Tumour Cell Properties for the Global Finger Printing Analysis of Human Pancreatic Carcinoma cDNA Libraries,” Biomedl. Health Res., 24:171-181 (1998).
Guo et al., “Direct flourescence analysis of gentic polymorphisms by hybridization with oligonucleotide arrays on glass supports,” Nucleic Acids Research, 22(24):5456-5465 (1994).
Hoffman, R., “The Three-Dimensional Question: Can Clinically Relevant Tumor Drug Resistance be Measured In Vitro?” Cancer and Metastasis Reviews, 13(2):169-173 (1994).
International Search Report for PCT/US01/32540 dated Apr. 18, 2002.
International Search Report for PCT/US97/11595 dated Aug. 17, 1998.
Kaaijk, P., et al., “Daunorubicin and Dozorubicin but not BCNU have Deleterious Effects on Organotypic Multicellular Spheroids of Gliomas,” British J. of Cancer, 74(2):187-193 (1996).
Kitmura, M., et al., “Chemosensitivity of Gastric Cancer Using Adhesive Tumor Cell Culture System,” Oncology Reports, 2(1):27-31 (1995).
Kornblith, P., “Role of Tissue Culture in Prediction Malignancy,” Clinical Neurosurgery, 25:346-376 (1978).
Kornblith, P., et al., “Variations in Response of Human Brain Tumors to BCNU In Vitro,” Journal of Neurosurgery, 48(4):580-586 (1978).
Kruczynski, A., et al., “Evidence of a Direct Relationship Between the Increase in the In Vitro Passage Number of Human Non-Small-Cell-Lung Cancer Primocultures and their Chemosensitivity,” Anticancer Research, 13:507-514 (1993).
McGuire, William L. et al., “In Vitro Assays to Predict Drug Sensitivity and Drug Resistance”, Breast Cancer Research and Treatment, 12:7-21 (1988).
Nance, K., et al., “Immunocytochemical Panel for the Identification of Malignant Cells in Serous Effusions,” Am. J. Clin. Pathol., 95:867-874 (1991).
Persons, D., et al., “Interphase Molecular Cytogenetic
Cooley Godward Kronish LLP
Gitomer Ralph
Precision Therapeutics, Inc.
LandOfFree
Method for selecting therapeutic agents for cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for selecting therapeutic agents for cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for selecting therapeutic agents for cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3911932